Recent studies have focused on the intersection of GLP|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine neurotransmission. While GCGR agonists are widely employed for addressing type 2 diabetes mellitus, their unexpected effects on reward circuits, specifically g